AnaptysBio, Inc. (ANAB)
| Market Cap | 1.95B +209.0% |
| Revenue (ttm) | 234.60M +157.0% |
| Net Income | -13.23M |
| EPS | -0.46 |
| Shares Out | 28.75M |
| PE Ratio | n/a |
| Forward PE | 76.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 504,136 |
| Open | 69.75 |
| Previous Close | 69.33 |
| Day's Range | 66.90 - 70.47 |
| 52-Week Range | 17.11 - 73.30 |
| Beta | 0.48 |
| Analysts | Buy |
| Price Target | 71.50 (+5.27%) |
| Earnings Date | May 22, 2026 |
About ANAB
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid ... [Read more]
Financial Performance
In 2025, AnaptysBio's revenue was $234.60 million, an increase of 157.01% compared to the previous year's $91.28 million. Losses were -$13.23 million, -90.89% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ANAB stock is "Buy." The 12-month stock price target is $71.5, which is an increase of 5.27% from the latest price.
News
AnaptysBio appoints Christopher Murphy as CFO
AnaptysBio (ANAB) announced the appointment of Christopher Murphy as CFO and Owen Hughes as a member of its board of directors. Murphy previously served as CFO and CBO of Third…
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announce...
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announce...
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
Piper Sandler lowered the firm’s price target on AnaptysBio (ANAB) to $93 from $95 and keeps an Overweight rating on the shares. The firm notes that on April 2026, AnaptysBio…
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab...
AnaptysBio price target raised to $85 from $66 at Leerink
Leerink raised the firm’s price target on AnaptysBio (ANAB) to $85 from $66 and keeps an Outperform rating on the shares.
GSK’s TESARO provides update on AnaptysBio litigation
GSK (GSK) subsidiary, TESARO, confirms that the Delaware Chancery Court has granted the motion to dismiss filed by AnaptysBio (ANAB) against TESARO’s claim for anticipatory breach. The court’s ruling ...
Delaware court dismisses Tesaro breach of contract claim against AnaptysBio
AnaptysBio (ANAB) announced that the Delaware Chancery Court has dismissed Tesaro’s anticipatory breach of contract claim against Anaptys. The ruling agrees with Anaptys’ position that it has never re...
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim
SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announ...
AnaptysBio price target lowered to $60 from $90 at UBS
UBS lowered the firm’s price target on AnaptysBio (ANAB) to $60 from $90 and keeps a Buy rating on the shares.
AnaptysBio price target lowered to $63 from $79 at Barclays
Barclays lowered the firm’s price target on AnaptysBio (ANAB) to $63 from $79 and keeps an Overweight rating on the shares. Following the spinoff, AnaptysBio is a pureplay royalty company…
AnaptysBio price target lowered to $60 from $90 at UBS
UBS lowered the firm’s price target on AnaptysBio (ANAB) to $60 from $90 and keeps a Buy rating on the shares. Following the spin-off of its biopharma business into First…
AnaptysBio completes separation of First Tracks Biotherapeutics
AnaptysBio (ANAB), announced the completion of its spin-off of First Tracks Biotherapeutics, its former biopharma operations business. “Anaptys begins this next chapter in a virtual business model. We...
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its f...
AnaptysBio price target raised to $95 from $67 at Piper Sandler
Piper Sandler raised the firm’s price target on AnaptysBio (ANAB) to $95 from $67 and keeps an Overweight rating on the shares. The firm notes AnaptysBio has traded up about…
AnaptysBio announces $100M share repurchase program
AnaptysBio (ANAB) announced that its board of directors has authorized a stock repurchase plan under which the company may repurchase up to $100M of the company’s outstanding common stock, par…
AnaptysBio board approves spin-off of First Tracks Biotherapeutics
AnaptysBio (ANAB) announced that its board of directors has approved the previously announced spin-off of First Tracks Biotherapeutics. The new company is expected to begin “regular-way” trading on Na...
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has approved the previously announced spin-off of First Tracks Biotherapeutics...
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase ...
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First Tracks Biotherapeutics, Inc. (“First Tracks Bio”), and EcoR1 Capital (the...
AnaptysBio price target raised to $90 from $70 at UBS
UBS raised the firm’s price target on AnaptysBio (ANAB) to $90 from $70 and keeps a Buy rating on the shares. Valuation for the company breaks down to roughly $35-$40…
AnaptysBio Transcript: Leerink Global Healthcare Conference 2026
A corporate split will create a royalty-focused parent and a biopharma spin-off, with the latter advancing ANB033 in celiac disease and EoE. Jemperli royalties are set to grow rapidly, and key clinical data for ANB033 is expected in Q4. Litigation with GSK could impact future royalty streams.
AnaptysBio Transcript: Barclays 28th Annual Global Healthcare Conference
A major restructuring will create a new biopharma company focused on advancing antibody programs, while the legacy entity becomes a high-margin royalty business. Key assets include ANB033 for celiac disease and EoE, with pivotal data expected in late 2024 and 2027, and a robust royalty stream from Jemperli.
AnaptysBio price target raised to $50 from $36 at Truist
Truist raised the firm’s price target on AnaptysBio (ANAB) to $50 from $36 and keeps a Hold rating on the shares. The firm is updating its target to reflect the…
AnaptysBio price target raised to $85 from $56 at Stifel
Stifel analyst Alex Thompson raised the firm’s price target on AnaptysBio (ANAB) to $85 from $56 and keeps a Buy rating on the shares. Following AnaptysBio’s Q4 update, the firm…